Galectin Therapeutics, Inc.

Galectin Sciences, LLC

Providence Health & Services - Oregon

Galeotin Therapeutics, Inc.

Peter G Traber

Eliezer Zomer

Anatole A Klyosov

Elena Chekhova

Joseph M Johnson

Sharon Shechter

Raphael Nir

Ryan George

William L Redmond

Stefanie N Linch

Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.

Compounds for the prevention and treatment of medical disorders and uses thereof

Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.

Compounds for the prevention and treatment of diseases and the use thereof

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

Methods for treatment of arthritis

Composition of novel carbohydrate drug for treatment of human diseases

Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.

Method for enhancing specific immunotherapies in cancer treatment

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-&#x3b1;-L-arabinose (Ara) residues.

Methods and compositions of the invention relate to the treatment of pulmonary fibrosis.

Method for treatment of pulmonary fibrosis

Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.

Growing community of inventors

Duluth, GA, United States of America

Peter G Traber